Oncology Analytics Raises $28 Million Series C Financing Led by Baird Capital
National healthcare investor Baird Capital joins existing investors Oak HC/FT, McKesson Ventures and The Blue Venture Fund
Oncology 2020: Key Challenges That Will Impact Health Plans
Data Driven Utilization Management, Purpose Built for Oncology
Oncology Analytics® provides health plans, providers, and patients with a data-driven, utilization management solution that delivers real-world, evidence-based analytics focused exclusively for oncology
Oncology Analytics named to CB Insights’ Digital Health 150
The most promising 150 private digital health startups working to transform the healthcare industry with new models of primary care to emerging tech solutions for providers
Oncology Analytics provides the critical missing link for health plans by helping to manage the total cost of cancer care. By providing access to current, evidence-based, disease-specific analytics on all cancer types and treatment options, backed by board-certified oncology physicians and pharmacists, health plans are able to provide their members with the ability to achieve the best possible outcomes.
National healthcare investor Baird Capital joins existing investors Oak HC/FT, McKesson Ventures and The Blue Venture Fund Atlanta, GA, May 26, 2020 — Oncology Analytics, a leading data analytics and technology-enabled services company dedicated to helping health...
Former Dana-Farber Associate Chief Medical Officer to Lead Company’s Clinical Team and Innovation Strategy
Articles & Press
CheckMate 9LA: Nivolumab and Ipilimumab plus 2 Cycles of Platinum-Doublet Chemotherapy vs. 4 Cycles of Chemotherapy as First-Line Treatment for Advanced Non-Small Cell Lung Cancer
The following article, written by Adam Peele, PharmD, MHA, BCPS, BCOP, Director of Pharmacy Operations at Oncology Analytics, is the second of a four-part series on key trends and findings from the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, held May 29-31, 2020.
KEYNOTE-355: Phase III study of pembrolizumab plus chemotherapy for previously untreated metastatic triple-negative breast cancer
The following article, written by Laura R. Bobolts, Senior Vice President of Pharmacy at Oncology Analytics, is the first of a four-part series on key trends and findings from the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, held in...
Date: October 20-21
Embassy Suites by Hilton
Fort Lauderdale, FL